Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo

British Journal of Cancer

Volumn 108, Issue 11, 2013, Pages 2291-2298

  Nielsen, T O ^a   Sorensen, S ^a,b   Dagnaes Hansen F ^b   Kjems, J ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Alternative splicing; Breast cancer; EGFR family; Erbb4; HER4; Splice switching oligonucleotide (SSO)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOENZYME; MESSENGER RNA; RECEPTOR TYROSINE PROTEIN KINASE ERBB 4; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4;

ALTERNATIVE RNA SPLICING; ANIMAL; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; C3H MOUSE; CELL STRAIN MCF 7; DRUG SCREENING; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; MOUSE; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ALTERNATIVE SPLICING; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; ISOENZYMES; MCF-7 CELLS; MICE; MICE, INBRED C3H; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; RANDOM ALLOCATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884198889     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.247     Document Type: Article

References (51)

1. Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarsky Y, Sudol M, Croce CM (2005) WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res 65(15): 6764–6772.
2. Bauman JA, Li SD, Yang A, Huang L, Kole R (2010) Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res 38(22): 8348–8356.
3. Carpenter G (2003) ErbB-4: mechanism of action and biology. Exp Cell Res 284(1): 66–77.
4. Cartegni L, Krainer AR (2003) Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 10(2): 120–125.
5. Cheng QC, Tikhomirov O, Zhou W, Carpenter G (2003) Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment. J Biol Chem 278(40): 38421–38427.
6. Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, Klagsbrun M (1999) Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 18(16): 2607–2615.
7. Elenius K, Corfas G, Paul S, Choi CJ, Rio C, Plowman GD, Klagsbrun M (1997) A novel juxtamembrane domain isoform of HER4/ErbB4. Isoformspecific tissue distribution and differential processing in response to phorbol ester. J Biol Chem 272(42): 26761–26768.
8. Ferretti E, Di ML, Gessi M, Mattei T, Greco A, Po A, De SE, Giangaspero F, Riccardi R, Di RC, Pazzaglia S, Maroder M, Alimandi M, Screpanti I, Gulino A (2006) Alternative splicing of the ErbB-4 cytoplasmic domain and its regulation by hedgehog signaling identify distinct medulloblastoma subsets. Oncogene 25(55): 7267–7273.
9. Graziewicz MA, Tarrant TK, Buckley B, Roberts J, Fulton L, Hansen H, Orum H, Kole R, Sazani P (2008) An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. Mol Ther 16(7): 1316–1322.
10. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4(5): 361–370.
11. Hollmen M, Elenius K (2010) Potential of ErbB4 antibodies for cancer therapy. Future Oncol 6(1): 37–53.
12. Hollmen M, Maatta JA, Bald L, Sliwkowski MX, Elenius K (2009) Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene 28(10): 1309–1319.
13. Hynes NE, Macdonald G (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21(2): 177–184.
14. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Harkonen P, Joensuu H, Isola J, Elenius K (2005) Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 65(4): 1384–1393.
15. Kainulainen V, Sundvall M, Maatta JA, Santiestevan E, Klagsbrun M, Elenius K (2000) A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 275(12): 8641–8649.
16. Khoo B, Roca X, Chew SL, Krainer AR (2007) Antisense oligonucleotideinduced alternative splicing of the APOB mRNA generates a novel isoform of APOB. BMC Mol Biol 8: 3.
17. Komuro A, Nagai M, Navin NE, Sudol M (2003) WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 278(35): 33334–33341.
18. Kurppa K, Elenius K (2009) Mutated ERBB4: a novel drug target in metastatic melanoma? Pigment Cell Melanoma Res 22(6): 708–710.
19. Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, Gaffney DK (2005) Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (PAkt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 99(2): 415–421.
20. Lee JC, Wang ST, Chow NH, Yang HB (2002) Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 38(8): 1065–1071.
21. Memon AA, Sorensen BS, Melgard P, Fokdal L, Thykjaer T, Nexo E (2004) Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer 91(12): 2034–2041.
22. Mill CP, Gettinger KL, Riese DJ (2011a) Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res 317(4): 392–404.
23. Mill CP, Zordan MD, Rothenberg SM, Settleman J, Leary JF, Riese DJ (2011b) ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer. Genes Cancer 2(8): 792–804.
24. Muraoka-Cook RS, Sandahl MA, Strunk KE, Miraglia LC, Husted C, Hunter DM, Elenius K, Chodosh LA, Earp HS (2009) ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol Cell Biol 29(18): 4935–4948.
25. Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JM, Jones FE (2006) The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 66(12): 6412–6420.
26. Ni CY, Murphy MP, Golde TE, Carpenter G (2001) gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294(5549): 2179–2181.
27. Omerovic J, Santangelo L, Puggioni EM, Marrocco J, Dall’Armi C, Palumbo C, Belleudi F, Di ML, Frati L, Torrisi MR, Cesareni G, Gulino A, Alimandi M (2007) The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation. FASEB J 21(11): 2849–2862.
28. Paatero I, Lassus H, Junttila TT, Kaskinen M, Butzow R, Elenius K (2013) CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Gynecol Oncol 129(1): 179–187.
29. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y (2009) Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41(10): 1127–1132.
30. Rio C, Buxbaum JD, Peschon JJ, Corfas G (2000) Tumor necrosis factoralpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 275(14): 10379–10387.
31. Roberts J, Palma E, Sazani P, Orum H, Cho M, Kole R (2006) Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther 14(4): 471–475.
32. Rudloff U, Samuels Y (2010) A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle 9(8): 1487–1503.
33. Saglam O, Shah V, Worsham MJ (2007) Molecular differentiation of early and late stage laryngeal squamous cell carcinoma: an exploratory analysis. Diagn Mol Pathol 16(4): 218–221.
34. Sazani P, Kole R (2003) Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 112(4): 481–486.
35. Scaffidi P, Misteli T (2005) Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 11(4): 440–445.
36. Settleman J (2009) A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin. Cancer Cell 16(4): 278–279.
37. Shi J, Yao D, Liu W, Wang N, Lv H, He N, Shi B, Hou P, Ji M (2012) Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci 13(4): 4714–4726.
38. Sierakowska H, Sambade MJ, Agrawal S, Kole R (1996) Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA 93(23): 12840–12844.
39. Sundvall M, Korhonen A, Paatero I, Gaudio E, Melino G, Croce CM, Aqeilan RI, Elenius K (2008) Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms Proc Natl Acad Sci USA 105(11): 4162–4167.
40. Sundvall M, Peri L, Maatta JA, Tvorogov D, Paatero I, Savisalo M, Silvennoinen O, Yarden Y, Elenius K (2007) Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Oncogene 26(48): 6905–6914.
41. Svasti S, Suwanmanee T, Fucharoen S, Moulton HM, Nelson MH, Maeda N, Smithies O, Kole R (2009) RNA repair restores hemoglobin expression in IVS2-654 thalassemic mice. Proc Natl Acad Sci USA 106(4): 1205–1210.
42. Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, Lippman ME (1999) Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res 59(20): 5315–5322.
43. Thybusch-Bernhardt A, Beckmann S, Juhl H (2001) Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. Int J Surg Investig 2(5): 393–400.
44. Uberall I, Kolar Z, Trojanec R, Berkovcova J, Hajduch M (2008) The status and role of ErbB receptors in human cancer. Exp Mol Pathol 84(2): 79–89.
45. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooi AJ, Goemans NM, de Kimpe SJ, Ekhart PF, Venneker EH, Platenburg GJ, Verschuuren JJ, van Ommen GJ (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357(26): 2677–2686.
46. Veikkolainen V, Vaparanta K, Halkilahti K, Iljin K, Sundvall M, Elenius K (2011) Function of ERBB4 is determined by alternative splicing. Cell Cycle 10(16): 2647–2657.
47. Williams T, Kole R (2006) Analysis of prostate-specific membrane antigen splice variants in LNCap cells. Oligonucleotides 16(2): 186–195.
48. Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, Li L, Katz RL, Hung MC (1999) Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5(12): 4164–4174.
49. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2): 127–137.
50. Zeng F, Xu J, Harris RC (2009) Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells. FASEB J 23(6): 1935–1945.
51. Zeng F, Zhang MZ, Singh AB, Zent R, Harris RC (2007) ErbB4 isoforms selectively regulate growth factor induced Madin-Darby canine kidney cell tubulogenesis. Mol Biol Cell 18(11): 4446–4456.